Friday, 16 October 2026European Markets

MAUNA KEA TECH Stock Bullish By 9% So Far On Thursday

Loading stream...

(vianews) - shares of mauna kea tech (cac 40: mkea.pa) rose 9.67% to €0.64 at 14:00 est on thursday, following the last session's downward trend. cac 40 is sliding 0.48% to €7,289.82, after two successive sessions in a row of losses. this seems, so far, a somewhat bearish trend trading session today.

mauna kea tech's last close was €0.58, 41.31% below its 52-week high of €0.99.

about mauna kea tech

mauna kea technologies sa develops and markets medical devices in europe, the middle east, africa, the united states, latin america, and asia. the company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. its flagship product is cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. the company was incorporated in 2000 and is headquartered in paris, france.

earnings per share

as for profitability, mauna kea tech has a trailing twelve months eps of €-0.418.

volatility

mauna kea tech's last week, last month's, and last quarter's current intraday variation average was a negative 0.11%, a negative 0.80%, and a positive 3.15%.

mauna kea tech's highest amplitude of average volatility was 2.44% (last week), 2.43% (last month), and 3.15% (last quarter).

volume

today's last reported volume for mauna kea tech is 694699 which is 102.78% above its average volume of 342584.

more news about mauna kea tech (mkea.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com